Machine learning-identified stemness features and constructed stemness-related subtype with prognosis, chemotherapy, and immunotherapy responses for non-small cell lung cancer patients

Aim This study aimed to explore a novel subtype classification method based on the stemness characteristics of patients with non-small cell lung cancer (NSCLC). Methods Based on the Cancer Genome Atlas database to calculate the stemness index (mRNAsi) of NSCLC patients, an unsupervised consensus clu...

Full description

Saved in:
Bibliographic Details
Published inStem cell research & therapy Vol. 14; no. 1; pp. 1 - 15
Main Authors Liu, Mingshan, Zhou, Ruihao, Zou, Wei, Yang, Zhuofan, Li, Quanjin, Chen, Zhiguo, jiang, Lei, Zhang, Jingtao
Format Journal Article
LanguageEnglish
Published London BioMed Central Ltd 07.09.2023
BioMed Central
BMC
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Aim This study aimed to explore a novel subtype classification method based on the stemness characteristics of patients with non-small cell lung cancer (NSCLC). Methods Based on the Cancer Genome Atlas database to calculate the stemness index (mRNAsi) of NSCLC patients, an unsupervised consensus clustering method was used to classify patients into two subtypes and analyze the survival differences, somatic mutational load, copy number variation, and immune characteristics differences between them. Subsequently, four machine learning methods were used to construct and validate a stemness subtype classification model, and cell function experiments were performed to verify the effect of the signature gene ARTN on NSCLC. Results Patients with Stemness Subtype I had better PFS and a higher somatic mutational burden and copy number alteration than patients with Stemness Subtype II. In addition, the two stemness subtypes have different patterns of tumor immune microenvironment. The immune score and stromal score and overall score of Stemness Subtype II were higher than those of Stemness Subtype I, suggesting a relatively small benefit to immune checkpoints. Four machine learning methods constructed and validated classification model for stemness subtypes and obtained multiple logistic regression equations for 22 characteristic genes. The results of cell function experiments showed that ARTN can promote the proliferation, invasion, and migration of NSCLC and is closely related to cancer stem cell properties. Conclusion This new classification method based on stemness characteristics can effectively distinguish patients' characteristics and thus provide possible directions for the selection and optimization of clinical treatment plans. Keywords: Non-small cell lung cancer, Cancer stem cell, Stemness index, Consensus clustering, Immunotherapy, Machine learning
AbstractList This study aimed to explore a novel subtype classification method based on the stemness characteristics of patients with non-small cell lung cancer (NSCLC). Based on the Cancer Genome Atlas database to calculate the stemness index (mRNAsi) of NSCLC patients, an unsupervised consensus clustering method was used to classify patients into two subtypes and analyze the survival differences, somatic mutational load, copy number variation, and immune characteristics differences between them. Subsequently, four machine learning methods were used to construct and validate a stemness subtype classification model, and cell function experiments were performed to verify the effect of the signature gene ARTN on NSCLC. This new classification method based on stemness characteristics can effectively distinguish patients' characteristics and thus provide possible directions for the selection and optimization of clinical treatment plans.
Aim This study aimed to explore a novel subtype classification method based on the stemness characteristics of patients with non-small cell lung cancer (NSCLC). Methods Based on the Cancer Genome Atlas database to calculate the stemness index (mRNAsi) of NSCLC patients, an unsupervised consensus clustering method was used to classify patients into two subtypes and analyze the survival differences, somatic mutational load, copy number variation, and immune characteristics differences between them. Subsequently, four machine learning methods were used to construct and validate a stemness subtype classification model, and cell function experiments were performed to verify the effect of the signature gene ARTN on NSCLC. Results Patients with Stemness Subtype I had better PFS and a higher somatic mutational burden and copy number alteration than patients with Stemness Subtype II. In addition, the two stemness subtypes have different patterns of tumor immune microenvironment. The immune score and stromal score and overall score of Stemness Subtype II were higher than those of Stemness Subtype I, suggesting a relatively small benefit to immune checkpoints. Four machine learning methods constructed and validated classification model for stemness subtypes and obtained multiple logistic regression equations for 22 characteristic genes. The results of cell function experiments showed that ARTN can promote the proliferation, invasion, and migration of NSCLC and is closely related to cancer stem cell properties. Conclusion This new classification method based on stemness characteristics can effectively distinguish patients' characteristics and thus provide possible directions for the selection and optimization of clinical treatment plans. Keywords: Non-small cell lung cancer, Cancer stem cell, Stemness index, Consensus clustering, Immunotherapy, Machine learning
Abstract Aim This study aimed to explore a novel subtype classification method based on the stemness characteristics of patients with non-small cell lung cancer (NSCLC). Methods Based on the Cancer Genome Atlas database to calculate the stemness index (mRNAsi) of NSCLC patients, an unsupervised consensus clustering method was used to classify patients into two subtypes and analyze the survival differences, somatic mutational load, copy number variation, and immune characteristics differences between them. Subsequently, four machine learning methods were used to construct and validate a stemness subtype classification model, and cell function experiments were performed to verify the effect of the signature gene ARTN on NSCLC. Results Patients with Stemness Subtype I had better PFS and a higher somatic mutational burden and copy number alteration than patients with Stemness Subtype II. In addition, the two stemness subtypes have different patterns of tumor immune microenvironment. The immune score and stromal score and overall score of Stemness Subtype II were higher than those of Stemness Subtype I, suggesting a relatively small benefit to immune checkpoints. Four machine learning methods constructed and validated classification model for stemness subtypes and obtained multiple logistic regression equations for 22 characteristic genes. The results of cell function experiments showed that ARTN can promote the proliferation, invasion, and migration of NSCLC and is closely related to cancer stem cell properties. Conclusion This new classification method based on stemness characteristics can effectively distinguish patients' characteristics and thus provide possible directions for the selection and optimization of clinical treatment plans.
AimThis study aimed to explore a novel subtype classification method based on the stemness characteristics of patients with non-small cell lung cancer (NSCLC).MethodsBased on the Cancer Genome Atlas database to calculate the stemness index (mRNAsi) of NSCLC patients, an unsupervised consensus clustering method was used to classify patients into two subtypes and analyze the survival differences, somatic mutational load, copy number variation, and immune characteristics differences between them. Subsequently, four machine learning methods were used to construct and validate a stemness subtype classification model, and cell function experiments were performed to verify the effect of the signature gene ARTN on NSCLC.ResultsPatients with Stemness Subtype I had better PFS and a higher somatic mutational burden and copy number alteration than patients with Stemness Subtype II. In addition, the two stemness subtypes have different patterns of tumor immune microenvironment. The immune score and stromal score and overall score of Stemness Subtype II were higher than those of Stemness Subtype I, suggesting a relatively small benefit to immune checkpoints. Four machine learning methods constructed and validated classification model for stemness subtypes and obtained multiple logistic regression equations for 22 characteristic genes. The results of cell function experiments showed that ARTN can promote the proliferation, invasion, and migration of NSCLC and is closely related to cancer stem cell properties.ConclusionThis new classification method based on stemness characteristics can effectively distinguish patients' characteristics and thus provide possible directions for the selection and optimization of clinical treatment plans.
This study aimed to explore a novel subtype classification method based on the stemness characteristics of patients with non-small cell lung cancer (NSCLC).AIMThis study aimed to explore a novel subtype classification method based on the stemness characteristics of patients with non-small cell lung cancer (NSCLC).Based on the Cancer Genome Atlas database to calculate the stemness index (mRNAsi) of NSCLC patients, an unsupervised consensus clustering method was used to classify patients into two subtypes and analyze the survival differences, somatic mutational load, copy number variation, and immune characteristics differences between them. Subsequently, four machine learning methods were used to construct and validate a stemness subtype classification model, and cell function experiments were performed to verify the effect of the signature gene ARTN on NSCLC.METHODSBased on the Cancer Genome Atlas database to calculate the stemness index (mRNAsi) of NSCLC patients, an unsupervised consensus clustering method was used to classify patients into two subtypes and analyze the survival differences, somatic mutational load, copy number variation, and immune characteristics differences between them. Subsequently, four machine learning methods were used to construct and validate a stemness subtype classification model, and cell function experiments were performed to verify the effect of the signature gene ARTN on NSCLC.Patients with Stemness Subtype I had better PFS and a higher somatic mutational burden and copy number alteration than patients with Stemness Subtype II. In addition, the two stemness subtypes have different patterns of tumor immune microenvironment. The immune score and stromal score and overall score of Stemness Subtype II were higher than those of Stemness Subtype I, suggesting a relatively small benefit to immune checkpoints. Four machine learning methods constructed and validated classification model for stemness subtypes and obtained multiple logistic regression equations for 22 characteristic genes. The results of cell function experiments showed that ARTN can promote the proliferation, invasion, and migration of NSCLC and is closely related to cancer stem cell properties.RESULTSPatients with Stemness Subtype I had better PFS and a higher somatic mutational burden and copy number alteration than patients with Stemness Subtype II. In addition, the two stemness subtypes have different patterns of tumor immune microenvironment. The immune score and stromal score and overall score of Stemness Subtype II were higher than those of Stemness Subtype I, suggesting a relatively small benefit to immune checkpoints. Four machine learning methods constructed and validated classification model for stemness subtypes and obtained multiple logistic regression equations for 22 characteristic genes. The results of cell function experiments showed that ARTN can promote the proliferation, invasion, and migration of NSCLC and is closely related to cancer stem cell properties.This new classification method based on stemness characteristics can effectively distinguish patients' characteristics and thus provide possible directions for the selection and optimization of clinical treatment plans.CONCLUSIONThis new classification method based on stemness characteristics can effectively distinguish patients' characteristics and thus provide possible directions for the selection and optimization of clinical treatment plans.
ArticleNumber 238
Audience Academic
Author Yang, Zhuofan
Liu, Mingshan
Zou, Wei
jiang, Lei
Li, Quanjin
Chen, Zhiguo
Zhou, Ruihao
Zhang, Jingtao
Author_xml – sequence: 1
  givenname: Mingshan
  surname: Liu
  fullname: Liu, Mingshan
– sequence: 2
  givenname: Ruihao
  surname: Zhou
  fullname: Zhou, Ruihao
– sequence: 3
  givenname: Wei
  surname: Zou
  fullname: Zou, Wei
– sequence: 4
  givenname: Zhuofan
  surname: Yang
  fullname: Yang, Zhuofan
– sequence: 5
  givenname: Quanjin
  surname: Li
  fullname: Li, Quanjin
– sequence: 6
  givenname: Zhiguo
  surname: Chen
  fullname: Chen, Zhiguo
– sequence: 7
  givenname: Lei
  surname: jiang
  fullname: jiang, Lei
– sequence: 8
  givenname: Jingtao
  surname: Zhang
  fullname: Zhang, Jingtao
BookMark eNp9k21r1TAUx4tM3Jz7Ar4KCKKwzjRJk_bVGMOHCxPBh9chTU_bjDapSareb-bHM_feDe8dYgttOf39_-eBnKfZkXUWsux5gS-KouJvQkFJJXJMaI4pwzxnj7KTQpQi52VBjva-j7OzEG5xuijFmLMn2TEVXDCCyUn2-6PSg7GARlDeGtvnpgUbTWegRSHCZCEE1IGKi4eAlG2RdjZEv-i4R-QeRrUNLE1cz4B-mjig2bveumDCOdIDTC4O4NW8Pt_amGla7H0IJfM5-aYUnfMo9ZqHSY0j0pAe42J7pJXV4NGsokkFhmfZ406NAc7u3qfZt3dvv15_yG8-vV9dX93kmmMe87asgWpdC1o3XcfbmuGybLqW4gKD4FXDStEUijCFCXRQY81arLSucNVQTgQ9zVY739apWzl7Mym_lk4ZuQ0430vlo9EjSE4Yx0CampWE6ZqqSnUNbrloNaOMVsnrcuc1L80ErU59eDUemB7-sWaQvfshC8wqKiqeHF7dOXj3fYEQ5WTCZkbKgluCJBUnRV3jcpPsxQP01i3eplltqDL1XRXkL9Wr1IGxnUuJ9cZUXglORaqb1Ym6-AeV7hYmk84DdCbFDwSvDwSJifAr9moJQa6-fD5kX-6xA6gxDsGNSzTpQByC1Q7U3oXgoZPaRLXBUjVmTFOSm9WQu9WQaTXkdjUkS1LyQHo_9P-I_gDT7hPP
CitedBy_id crossref_primary_10_2174_0109298673278775231101064235
crossref_primary_10_1002_imo2_14
crossref_primary_10_1111_cas_16384
Cites_doi 10.1016/j.jtho.2019.07.031
10.21037/tlcr.2017.08.08
10.1016/j.cell.2017.10.049
10.1016/j.jtho.2015.09.009
10.1126/scitranslmed.3005723
10.1002/sim.3148
10.1038/nature12930
10.1172/JCI41004
10.1158/1541-7786.MCR-05-0104
10.1038/s41598-018-30525-3
10.1093/nar/gkw1092
10.1093/bib/bbx124
10.2147/CMAR.S232632
10.6004/jnccn.2022.0025
10.1093/nar/gkx356
10.1504/IJDMB.2014.064889
10.3322/caac.21262
10.3389/fgene.2019.01077
10.1016/j.mam.2013.08.003
10.1097/JTO.0b013e3182037b76
10.1172/JCI90429
10.3389/fimmu.2018.03101
10.1016/j.ctrv.2012.02.013
10.4049/jimmunol.1500447
10.1016/j.cell.2018.03.034
10.1038/75556
10.1093/bioinformatics/btq170
10.1038/s41586-019-1032-7
10.1200/JCO.2014.59.4358
10.1371/journal.pcbi.1004790
10.3322/caac.21442
10.1158/1535-7163.MCT-09-1077
10.1038/s41591-018-0136-1
10.1186/1471-2105-14-7
10.1186/s12935-018-0641-9
10.1038/ncomms11914
10.1016/B978-0-12-416022-4.00008-1
10.1001/jamanetworkopen.2019.6879
10.1164/rccm.201207-1180OC
10.1016/j.bcp.2013.04.003
10.1186/s12885-018-4389-3
10.1038/ncomms3612
10.1038/nm0901-1028
10.1016/j.cell.2013.10.029
10.7150/jca.20821
ContentType Journal Article
Copyright COPYRIGHT 2023 BioMed Central Ltd.
2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2023. BioMed Central Ltd., part of Springer Nature.
BioMed Central Ltd., part of Springer Nature 2023
Copyright_xml – notice: COPYRIGHT 2023 BioMed Central Ltd.
– notice: 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2023. BioMed Central Ltd., part of Springer Nature.
– notice: BioMed Central Ltd., part of Springer Nature 2023
DBID AAYXX
CITATION
ISR
3V.
7X7
7XB
88E
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M1P
M7P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s13287-023-03406-4
DatabaseName CrossRef
Gale In Context: Science
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Biological Science Collection
ProQuest Health & Medical Collection
Medical Database
Biological Science Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList


Publicly Available Content Database

MEDLINE - Academic

Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1757-6512
EndPage 15
ExternalDocumentID oai_doaj_org_article_62460e2b94524c93a8afb0d67dc43438
PMC10483786
A763734349
10_1186_s13287_023_03406_4
GeographicLocations Taiwan
GeographicLocations_xml – name: Taiwan
GroupedDBID ---
0R~
53G
5VS
7X7
88E
8FE
8FH
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAYXX
ABDBF
ABUWG
ACGFS
ACIHN
ACJQM
ACPRK
ACUHS
ADBBV
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIAM
AOIJS
BAPOH
BAWUL
BBNVY
BCNDV
BENPR
BFQNJ
BHPHI
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
DIK
E3Z
EBD
EBLON
EBS
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HCIFZ
HMCUK
HYE
IAO
IEA
IHR
IHW
INH
INR
ISR
ITC
KQ8
LK8
M1P
M7P
M~E
O5R
O5S
OK1
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
ROL
RPM
RSV
SBL
SOJ
SV3
TUS
UKHRP
PMFND
3V.
7XB
8FK
AZQEC
DWQXO
GNUQQ
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c606t-d59e3cc9739bff6d94055bfd3010e768b457b1a24a02efe90c4d0acc808b36273
IEDL.DBID DOA
ISSN 1757-6512
IngestDate Wed Aug 27 01:31:24 EDT 2025
Thu Aug 21 18:36:30 EDT 2025
Tue Aug 05 11:27:30 EDT 2025
Fri Jul 25 10:23:14 EDT 2025
Tue Jun 17 22:26:23 EDT 2025
Tue Jun 10 21:20:51 EDT 2025
Fri Jun 27 06:07:32 EDT 2025
Thu May 22 21:19:58 EDT 2025
Thu Apr 24 23:10:08 EDT 2025
Tue Jul 01 02:42:19 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c606t-d59e3cc9739bff6d94055bfd3010e768b457b1a24a02efe90c4d0acc808b36273
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://doaj.org/article/62460e2b94524c93a8afb0d67dc43438
PMID 37674202
PQID 2865457812
PQPubID 2040189
PageCount 15
ParticipantIDs doaj_primary_oai_doaj_org_article_62460e2b94524c93a8afb0d67dc43438
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10483786
proquest_miscellaneous_2862199058
proquest_journals_2865457812
gale_infotracmisc_A763734349
gale_infotracacademiconefile_A763734349
gale_incontextgauss_ISR_A763734349
gale_healthsolutions_A763734349
crossref_citationtrail_10_1186_s13287_023_03406_4
crossref_primary_10_1186_s13287_023_03406_4
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-09-07
PublicationDateYYYYMMDD 2023-09-07
PublicationDate_xml – month: 09
  year: 2023
  text: 2023-09-07
  day: 07
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
PublicationTitle Stem cell research & therapy
PublicationYear 2023
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References W Sauerbrei (3406_CR28) 2007; 26
A Subramanian (3406_CR27) 2017; 171
KT Leeman (3406_CR6) 2014; 107
A Sokolov (3406_CR19) 2016; 12
F Degenhardt (3406_CR30) 2019; 20
S Zhou (3406_CR8) 2001; 7
S Hanzelmann (3406_CR25) 2013; 14
K Yoshihara (3406_CR20) 2013; 4
MA Postow (3406_CR17) 2015; 33
G Papafotiou (3406_CR41) 2016; 7
S Singh (3406_CR35) 2014; 39
B Zhou (3406_CR42) 2018; 128
W Li (3406_CR31) 2019; 10
B Shiotani (3406_CR9) 2006; 4
P Jiang (3406_CR26) 2018; 24
C Ju (3406_CR33) 2018; 18
J Wang (3406_CR23) 2017; 45
S Rousseaux (3406_CR18) 2013; 5
CT Yeh (3406_CR39) 2012; 186
YP Hu (3406_CR38) 2013; 85
R Zhou (3406_CR34) 2020; 12
X Wu (3406_CR36) 2012; 38
RL Siegel (3406_CR2) 2018; 68
R Rosenthal (3406_CR11) 2019; 567
BJ Morrison (3406_CR14) 2018; 18
J Malhotra (3406_CR45) 2017; 6
RM Bremnes (3406_CR7) 2011; 6
TM Malta (3406_CR40) 2018; 173
FG Giancotti (3406_CR4) 2013; 155
NY Frank (3406_CR37) 2010; 120
M Szarynska (3406_CR16) 2018; 8
E Ames (3406_CR15) 2015; 195
M Kanehisa (3406_CR22) 2017; 45
Y Yu (3406_CR44) 2019; 2
DS Ettinger (3406_CR3) 2022; 20
C Zhang (3406_CR12) 2019; 14
JZ Tang (3406_CR43) 2010; 9
TJ Desai (3406_CR5) 2014; 507
M Ashburner (3406_CR21) 2000; 25
B Stankovic (3406_CR10) 2018; 9
S Kim (3406_CR29) 2014; 10
MD Wilkerson (3406_CR24) 2010; 26
LA Torre (3406_CR1) 2015; 65
X Zhang (3406_CR13) 2018; 9
P Goldstraw (3406_CR32) 2016; 11
References_xml – volume: 14
  start-page: 1912
  issue: 11
  year: 2019
  ident: 3406_CR12
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2019.07.031
– volume: 6
  start-page: 612
  issue: 5
  year: 2017
  ident: 3406_CR45
  publication-title: Transl Lung Cancer Res
  doi: 10.21037/tlcr.2017.08.08
– volume: 171
  start-page: 1437
  issue: 6
  year: 2017
  ident: 3406_CR27
  publication-title: Cell
  doi: 10.1016/j.cell.2017.10.049
– volume: 11
  start-page: 39
  issue: 1
  year: 2016
  ident: 3406_CR32
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2015.09.009
– volume: 5
  start-page: 186ra166
  issue: 186
  year: 2013
  ident: 3406_CR18
  publication-title: Sci Transl Med
  doi: 10.1126/scitranslmed.3005723
– volume: 26
  start-page: 5512
  issue: 30
  year: 2007
  ident: 3406_CR28
  publication-title: Stat Med
  doi: 10.1002/sim.3148
– volume: 507
  start-page: 190
  issue: 7491
  year: 2014
  ident: 3406_CR5
  publication-title: Nature
  doi: 10.1038/nature12930
– volume: 120
  start-page: 41
  issue: 1
  year: 2010
  ident: 3406_CR37
  publication-title: J Clin Invest
  doi: 10.1172/JCI41004
– volume: 4
  start-page: 125
  issue: 2
  year: 2006
  ident: 3406_CR9
  publication-title: Mol Cancer Res
  doi: 10.1158/1541-7786.MCR-05-0104
– volume: 8
  start-page: 12042
  issue: 1
  year: 2018
  ident: 3406_CR16
  publication-title: Sci Rep
  doi: 10.1038/s41598-018-30525-3
– volume: 45
  start-page: D353
  issue: D1
  year: 2017
  ident: 3406_CR22
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkw1092
– volume: 20
  start-page: 492
  issue: 2
  year: 2019
  ident: 3406_CR30
  publication-title: Brief Bioinform
  doi: 10.1093/bib/bbx124
– volume: 12
  start-page: 531
  year: 2020
  ident: 3406_CR34
  publication-title: Cancer Manag Res
  doi: 10.2147/CMAR.S232632
– volume: 20
  start-page: 497
  issue: 5
  year: 2022
  ident: 3406_CR3
  publication-title: J Natl Compr Canc Netw
  doi: 10.6004/jnccn.2022.0025
– volume: 45
  start-page: W130
  issue: W1
  year: 2017
  ident: 3406_CR23
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkx356
– volume: 10
  start-page: 374
  issue: 4
  year: 2014
  ident: 3406_CR29
  publication-title: Int J Data Min Bioinform
  doi: 10.1504/IJDMB.2014.064889
– volume: 65
  start-page: 87
  issue: 2
  year: 2015
  ident: 3406_CR1
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21262
– volume: 10
  start-page: 1077
  year: 2019
  ident: 3406_CR31
  publication-title: Front Genet
  doi: 10.3389/fgene.2019.01077
– volume: 39
  start-page: 50
  year: 2014
  ident: 3406_CR35
  publication-title: Mol Aspects Med
  doi: 10.1016/j.mam.2013.08.003
– volume: 6
  start-page: 824
  issue: 4
  year: 2011
  ident: 3406_CR7
  publication-title: J Thorac Oncol
  doi: 10.1097/JTO.0b013e3182037b76
– volume: 128
  start-page: 970
  issue: 3
  year: 2018
  ident: 3406_CR42
  publication-title: J Clin Invest
  doi: 10.1172/JCI90429
– volume: 9
  start-page: 3101
  year: 2018
  ident: 3406_CR10
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2018.03101
– volume: 38
  start-page: 580
  issue: 6
  year: 2012
  ident: 3406_CR36
  publication-title: Cancer Treat Rev
  doi: 10.1016/j.ctrv.2012.02.013
– volume: 195
  start-page: 4010
  issue: 8
  year: 2015
  ident: 3406_CR15
  publication-title: J Immunol
  doi: 10.4049/jimmunol.1500447
– volume: 173
  start-page: 338
  issue: 2
  year: 2018
  ident: 3406_CR40
  publication-title: Cell
  doi: 10.1016/j.cell.2018.03.034
– volume: 25
  start-page: 25
  issue: 1
  year: 2000
  ident: 3406_CR21
  publication-title: Gene Ontol Consort Nat Genet
  doi: 10.1038/75556
– volume: 26
  start-page: 1572
  issue: 12
  year: 2010
  ident: 3406_CR24
  publication-title: Bioinformatics
  doi: 10.1093/bioinformatics/btq170
– volume: 567
  start-page: 479
  issue: 7749
  year: 2019
  ident: 3406_CR11
  publication-title: Nature
  doi: 10.1038/s41586-019-1032-7
– volume: 33
  start-page: 1974
  issue: 17
  year: 2015
  ident: 3406_CR17
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2014.59.4358
– volume: 12
  start-page: e1004790
  issue: 3
  year: 2016
  ident: 3406_CR19
  publication-title: PLoS Comput Biol
  doi: 10.1371/journal.pcbi.1004790
– volume: 68
  start-page: 7
  issue: 1
  year: 2018
  ident: 3406_CR2
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21442
– volume: 9
  start-page: 1697
  issue: 6
  year: 2010
  ident: 3406_CR43
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-09-1077
– volume: 24
  start-page: 1550
  issue: 10
  year: 2018
  ident: 3406_CR26
  publication-title: Nat Med
  doi: 10.1038/s41591-018-0136-1
– volume: 14
  start-page: 7
  year: 2013
  ident: 3406_CR25
  publication-title: BMC Bioinform
  doi: 10.1186/1471-2105-14-7
– volume: 18
  start-page: 141
  issue: 1
  year: 2018
  ident: 3406_CR33
  publication-title: Cancer Cell Int
  doi: 10.1186/s12935-018-0641-9
– volume: 7
  start-page: 11914
  year: 2016
  ident: 3406_CR41
  publication-title: Nat Commun
  doi: 10.1038/ncomms11914
– volume: 107
  start-page: 207
  year: 2014
  ident: 3406_CR6
  publication-title: Curr Top Dev Biol
  doi: 10.1016/B978-0-12-416022-4.00008-1
– volume: 2
  start-page: e196879
  issue: 7
  year: 2019
  ident: 3406_CR44
  publication-title: JAMA Netw Open
  doi: 10.1001/jamanetworkopen.2019.6879
– volume: 186
  start-page: 1180
  issue: 11
  year: 2012
  ident: 3406_CR39
  publication-title: Am J Respir Crit Care Med
  doi: 10.1164/rccm.201207-1180OC
– volume: 85
  start-page: 1619
  issue: 11
  year: 2013
  ident: 3406_CR38
  publication-title: Biochem Pharmacol
  doi: 10.1016/j.bcp.2013.04.003
– volume: 18
  start-page: 469
  issue: 1
  year: 2018
  ident: 3406_CR14
  publication-title: BMC Cancer
  doi: 10.1186/s12885-018-4389-3
– volume: 4
  start-page: 2612
  year: 2013
  ident: 3406_CR20
  publication-title: Nat Commun
  doi: 10.1038/ncomms3612
– volume: 7
  start-page: 1028
  issue: 9
  year: 2001
  ident: 3406_CR8
  publication-title: Nat Med
  doi: 10.1038/nm0901-1028
– volume: 155
  start-page: 750
  issue: 4
  year: 2013
  ident: 3406_CR4
  publication-title: Cell
  doi: 10.1016/j.cell.2013.10.029
– volume: 9
  start-page: 367
  issue: 2
  year: 2018
  ident: 3406_CR13
  publication-title: J Cancer
  doi: 10.7150/jca.20821
SSID ssj0000330064
Score 2.338588
Snippet Aim This study aimed to explore a novel subtype classification method based on the stemness characteristics of patients with non-small cell lung cancer...
This study aimed to explore a novel subtype classification method based on the stemness characteristics of patients with non-small cell lung cancer (NSCLC)....
AimThis study aimed to explore a novel subtype classification method based on the stemness characteristics of patients with non-small cell lung cancer...
This study aimed to explore a novel subtype classification method based on the stemness characteristics of patients with non-small cell lung cancer...
Abstract Aim This study aimed to explore a novel subtype classification method based on the stemness characteristics of patients with non-small cell lung...
SourceID doaj
pubmedcentral
proquest
gale
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
StartPage 1
SubjectTerms Algorithms
Analysis
B cells
Cancer
Cancer stem cell
Cancer therapies
Chemotherapy
Clustering
Consensus clustering
Copy number
Datasets
Genes
Genetic aspects
Genomes
Genomics
Immune checkpoint
Immunotherapy
Learning algorithms
Lung cancer
Lung cancer, Non-small cell
Lung cancer, Small cell
Machine learning
Medical prognosis
Microenvironments
Mutation
Non-small cell lung cancer
Non-small cell lung carcinoma
Patients
Radiation therapy
Regression analysis
Small cell lung carcinoma
Stem cells
Stemness index
Thoracic surgery
SummonAdditionalLinks – databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagCIkLKi8RKGAQEgdq1UmcxD6hgqgKEhyASnuzbMferrRNyqZ76D_rz2PG8S4NSL3ak1jJjOdhz3xDyFtnwQ8tc8OcLCBAaWTOjBOOQSRWF7nLS2titsX3-vhEfJ1Vs3TgNqS0yo1OjIq67R2ekR9gBaUA8cqLD-e_GXaNwtvV1ELjNrmD0GWY0tXMmu0ZC4dgHUzuplZG1gcDBF-wq8BQMV6CLWNiYo8ibP__yvnfhMlrFuhol9xPriM9HHn9gNzy3UNyd2wmefmIXH2LeZGepkYQc7Zox1Qg31KEa0alRoOPSJ4DNV1LXZ_wY69RsFjdggNri-ezFE9qKaZxdf2wGPYpcPkslW1d7sfXLLDGZDNEV2PWLSwB_jDt-o4NZ2a5pHhFQJegW6hDSVvRBOk6PCYnR59_fTpmqS8DcxDuXLC2Ur50TjWlsiHUrQKnr7KhBV3BPYQvFvhkc1MIwwsfvOJOtNw4J7m0YC-b8gnZgdX9U0JBI3gZJK88uDWFa2SlgpeVL4MMJqiQkXzDHe0SaDn2zljqGLzIWo8c1cBRHTmqRUbeb585HyE7bqT-iEzfUiLcdhzoV3Oddq-uC1FzX1glqkI4VRppguVt3bQOK3NlRl6hyOixdnWrNPQhaO8GCITKyJtIgZAbHeb0zM16GPSXnz8mRO8SUejhK51JJRLwrxCla0K5N6EEneCm0xvZ1UknDfrvDsrI6-00Pol5dp3v15EGTJjiFXySnMj85AdNZ7rFacQlz8f2BPWzm1d_Tu4VcQNi9dwe2QE59y_As7uwL-P2_QM-MVDS
  priority: 102
  providerName: ProQuest
Title Machine learning-identified stemness features and constructed stemness-related subtype with prognosis, chemotherapy, and immunotherapy responses for non-small cell lung cancer patients
URI https://www.proquest.com/docview/2865457812
https://www.proquest.com/docview/2862199058
https://pubmed.ncbi.nlm.nih.gov/PMC10483786
https://doaj.org/article/62460e2b94524c93a8afb0d67dc43438
Volume 14
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagCIkLKi8RKItBSByo1TycxD52UauCRIUWKq24WLZjtyttE9R0D_1n_XnMON7VBiS4cMnBnrw843kkM98Q8s4a8EOLTDMrcghQapExbbllEIlVeWazwuiQbXFanZzxz_NyvtXqC3PCBnjgYeEOqpxXqcuN5GXOrSy00N6kTVU3FosiQ5kv2LytYCroYAjTwdiuq2REddBD2AX7CUwUSwuwYoyPLFEA7P9TLf-eKrlle453ycPoNNLD4WEfkTuufUzuD20kb56Q2y8hI9LR2ALinC2aIQnINRSBmlGdUe8ChmdPddtQ20Xk2C0KFupacGBl8MssxW-0FBO42q5f9PsU-HsZC7Zu9sNlFlhdsh6iV0O-LdwCPGHadi3rL_VySfHnAF2CVqEWZeyKRjDX_ik5Oz76_vGExY4MzEKgc82aUrrCWlkX0nhfNRLcvdL4BrRE6iBwMbysTaZzrtPceSdTy5tUWytSYcBS1sUzsgN3d88JBV3ghBdp6cChyW0tSumdKF3hhdde-oRka-4oG-HKsWvGUoWwRVRq4KgCjqrAUcUT8mFzzs8BrOOv1FNk-oYSgbbDAIifiuKn_iV-CXmNIqOGqtWNulCHoLdrIOAyIW8DBYJttJjNc65Xfa8-fZuNiN5HIt_BW1odiyNgrRCfa0S5N6IEbWDH02vZVVEb9Qqrj4Ez4Msl5M1mGs_EDLvWdatAA8ZLpiW8khjJ_GiBxjPt4iIgkmdDY4Lqxf9Y0pfkQR62KVbX7ZEd2A3uFXh-12ZC7tbzekLuTY9Ov84mYcvDcTb98QuwZlwr
linkProvider Directory of Open Access Journals
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELbKVgguiKdYKNQgEAdqNQ8n6xwQaqFVl7YrVFqpN9dx7GWlbVI2XaH9U5z5ecw4ztKA1Fuv9iRWMuNvZux5EPJG52CHxqFiWkTgoAxEyJTmmoEnlkahDuNcuWiLUbp3wr-cJqcr5FebC4NhlS0mOqAuKo1n5JuYQclBvMLo48UPhl2j8Ha1baHRiMW-WfwEl63-MPwM_H0bRbs7x5_2mO8qwDQY65esSDITa50N4iy3Ni0yMFmS3BYg6YEB4zuHVfJQRVwFkbEmCzQvAqW1CEQOaD-I4b23yCqPwZXpkdXtndHXo-WpThDHqOTb7ByRbtbg7sE-BtXIghi0J-MdDegaBfyvDv4N0byi83bvk3veWKVbjXQ9ICumfEhuN-0rF4_I70MXiWmobz0xZpOiCT4yBcUC0Qij1BpXO7SmqiyornzF2isUzOXT4MA8xxNhimfDFAPHyqqe1BsU5OrcJ4otNtxrJpjV0g7RWRPnC0uABU7LqmT1uZpOKV5K0CmgGdUo2zPqi8jWj8nJjfDsCenB6uYpoYBBRlgRJAYMqUgPRJJZIxITW2GVzWyfhC13pPZl0rFbx1Q6d0mksuGoBI5Kx1HJ--T98pmLpkjItdTbyPQlJRb4dgPVbCw9Xsg04mlgojzjScR1FiuhbB4U6aDQmAss-mQdRUY22bJLmJJboC8GQMCzPnntKLDIR4lRRGM1r2s5_HbUIXrniWwFX6mVT8qAf4V1wTqUax1KQCHdnW5lV3oUrOXfPdsnr5bT-CRG9pWmmjsaUJpZkMAniY7Md35Qd6acfHeV0MOmIUL67PrV18mdvePDA3kwHO0_J3cjtxkxd2-N9EDmzQuwKy_zl34zU3J20_jxB8wojzM
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Machine+learning-identified+stemness+features+and+constructed+stemness-related+subtype+with+prognosis%2C+chemotherapy%2C+and+immunotherapy+responses+for+non-small+cell+lung+cancer+patients&rft.jtitle=Stem+cell+research+%26+therapy&rft.au=Liu%2C+Mingshan&rft.au=Zhou%2C+Ruihao&rft.au=Zou%2C+Wei&rft.au=Yang%2C+Zhuofan&rft.date=2023-09-07&rft.pub=BioMed+Central+Ltd&rft.issn=1757-6512&rft.eissn=1757-6512&rft.volume=14&rft.issue=1&rft_id=info:doi/10.1186%2Fs13287-023-03406-4&rft.externalDocID=A763734349
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1757-6512&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1757-6512&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1757-6512&client=summon